FATE - NASDAQ
Fate Therapeutics, Inc.
$2.25
-13%Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
At a Glance
Live SnapshotFate Therapeutics, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Negative gross margin indicates the company is losing money on each sale—unsustainable long-term.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
High margin compression: Large gap between gross and net margins suggests operational inefficiencies or heavy debt burden. Focus on expense management and deleveraging.
Fate Therapeutics, Inc. Income Statement
FATE • NASDAQ
| Fate Therapeutics, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | |||||||||||||||
6.6M | 13.6M | 63.5M | 96.3M | 55.8M | 31.4M | 10.7M | 4.7M | 4.1M | 4.4M | 2.4M | 0.0 | 971K | 2.7M | 1.2M | |
GROSS PROFIT | |||||||||||||||
(12.9M) | (0.0) | (157.2M) | (13.8M) | (5.9M) | (125.6M) | (87.8M) | (56M) | (34.4M) | (26.5M) | (19.9M) | (16.4M) | (12M) | (12M) | (0.0) | |
-6.3M | 13.6M | -93.7M | 82.5M | 50M | -94.2M | -77.1M | -51.3M | -30.3M | -22.1M | -17.4M | -16.4M | -11M | -9.3M | 1.2M | |
OPERATING INCOME | |||||||||||||||
(141.4M) | (223.9M) | (96.9M) | (390.9M) | (267M) | (33.9M) | (111.4M) | (71.8M) | (46.2M) | (36.4M) | (30.2M) | (24.9M) | (18.6M) | (16.2M) | (14.5M) | |
(46.5M) | (74.2M) | (96.9M) | (84.2M) | (57.3M) | (33.9M) | (23.6M) | (15.8M) | (11.9M) | (9.9M) | (10.4M) | (8.5M) | (6.6M) | (4.2M) | (4.6M) | |
(107.8M) | (135M) | (172.6M) | (320.5M) | (215.5M) | (125.6M) | (87.8M) | (56M) | (34.4M) | (26.5M) | (19.9M) | (16.4M) | (12M) | (12M) | (9.9M) | |
-147.7M | -210.3M | -190.5M | -308.4M | -217M | -128.1M | -100.7M | -67.1M | -42.1M | -32M | -27.8M | -24.9M | -17.7M | -13.6M | -13.3M | |
PRE-TAX INCOME | |||||||||||||||
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (1.8M) | (1.7M) | (1.3M) | (1.6M) | (2.2M) | (549K) | (796K) | (487K) | (127K) | |
11.1M | 17.3M | 17.2M | 5.8M | 1.3M | 2.4M | 2.6M | 494K | -709K | -1.5M | -2.2M | -547K | -790K | -486K | -125K | |
-12.9M | (14.7M) | -172.6M | -13.8M | -5.9M | -125.6M | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
11.4M | 24M | 29.6M | 26.7M | 4.8M | -45.3M | 2.6M | 494K | -827K | -1.5M | -2.2M | -979K | -3.2M | -682K | -134K | |
-136.3M | -186.3M | -160.9M | -281.7M | -212.2M | -173.4M | -98.1M | -66.6M | -43M | -33.5M | -30M | -25.9M | -20.9M | -14.2M | -13.4M | |
NET INCOME | |||||||||||||||
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -441K | (0.0) | (297K) | (0.0) | (0.0) | (53K) | (0.0) | (0.0) | (127K) | |
-136.3M | -186.3M | -160.9M | -281.7M | -212.2M | -173.4M | -97.7M | -66.6M | -43M | -33.5M | -30M | -25.9M | -20.9M | -14.2M | -13.4M |
SEC Filings
FATE - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 13, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 13, 2026 | May 13, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 24, 2026 | June 12, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 26, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 26, 2026 | February 26, 2026 | 2026 | |
10-Q 10-Q 2025 Q3 Q3 | November 13, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 13, 2025 | November 13, 2025 | 2025 | |
8-K 8-K 2025 N/A | October 27, 2025 | October 26, 2025 | 2025 | |
8-K 8-K 2025 N/A | October 14, 2025 | October 10, 2025 | 2025 | |
10-Q 10-Q 2025 Q2 Q2 | August 12, 2025 | June 30, 2025 | 2025 |
Related Guides
Continue your FATE research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.